PT-141 Palatin

Petter Hedlund

Research output: Contribution to journalArticle

Abstract

Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.

Original languageEnglish
Pages (from-to)456-462
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume5
Issue number4
Publication statusPublished - Apr 2004

    Fingerprint

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Hedlund, P. (2004). PT-141 Palatin. Current Opinion in Investigational Drugs, 5(4), 456-462.